Neurona Therapeutics Prepares for Key October Investor Engagements
Neurona Therapeutics, a pioneering clinical-stage biotherapeutics company dedicated to advancing regenerative cell therapies for nervous system disorders, is gearing up for an exciting month.
Upcoming Conferences
Cory R. Nicholas, Ph.D., the Co-Founder and Chief Executive Officer of Neurona, is set to engage with investors during notable conferences in October. These events offer valuable insights into the company's innovative approaches in neuroscience and regenerative medicine.
William Blair's Innovator Series
The first event, the 2024 William Blair's Innovator Series: Private Biotechnology Stars, will feature a fireside chat on Thursday, October 3. This virtual chat is an opportunity for potential investors to learn about Neurona's cutting-edge research and clinical advancements starting at 6:00 am PT / 8:00 am CT.
Leerink Partners Event
Following that, Neurona will participate in the Leerink Partners Biopharma Private Company Connect event. Scheduled for Tuesday, October 22, and Wednesday, October 23, these one-on-one investor meetings will allow for deeper discussions about the company's trajectory and growth potential, all conducted virtually.
Replay Availability
Investors who cannot attend the live fireside chat can access a replay through the News section of Neurona's website, where it will be available for seven days following the event. This accessibility ensures that even those unable to join live will not miss out on the critical updates and information shared by Neurona's leadership.
About Neurona Therapeutics
Neurona Therapeutics is at the forefront of developing allogeneic, off-the-shelf regenerative neural cell therapy products. These therapies hold the promise of long-term, targeted repair of the nervous system from a single administration. At the center of their clinical endeavors is the candidate NRTX-1001, which consists of GABAergic interneurons currently undergoing evaluation for safety and efficacy in two ongoing multicenter Phase 1/2 trials.
Clinical Trials Overview
This innovative candidate is being studied for drug-resistant unilateral mesial temporal lobe epilepsy and drug-resistant bilateral mesial temporal lobe epilepsy. Neurona also has plans for future indications including neocortical focal epilepsy. This is a significant stride towards addressing complex neurological conditions that have limited treatment options.
Funding and Support
The clinical trial for unilateral MTLE is further supported by an $8.0 million grant from the California Institute for Regenerative Medicine (CIRM). Notably, the FDA granted NRTX-1001 the Regenerative Medicine Advanced Therapy (RMAT) designation earlier in the year, a testament to the promising clinical data generated thus far.
Recent Developments
In an impressive funding round in February 2024, Neurona secured $120 million, co-led by influential investors, Viking Global Investors and Cormorant Asset Management. This infusion of capital is expected to propel the company’s mission of delivering advanced treatments aimed at repairing nervous system damage.
Investor Contact Information
For more details, interested parties can reach out to Laurence Watts at New Street Investor Relations. The investor contact email is available for those seeking further engagement regarding the company's trajectory and stock information.
Frequently Asked Questions
What is Neurona Therapeutics focused on?
Neurona Therapeutics specializes in regenerative cell therapies targeting nervous system disorders.
Who will be speaking at the conferences?
Cory R. Nicholas, Ph.D., the CEO, will represent Neurona at the upcoming conferences.
Where can I find replays of the investor events?
Replays will be available on the Neurona website's News section for seven days after the live events.
What is NRTX-1001?
NRTX-1001 is Neurona's lead product candidate, designed to treat drug-resistant mesial temporal lobe epilepsy.
How is Neurona funding its clinical trials?
The trials are supported by grants and recent funding, including an $8.0 million grant from CIRM.
